These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 18393777)
1. Recent clinical trials of cladribine in hematological malignancies and autoimmune disorders. Robak T; Wierzbowska A; Robak E Rev Recent Clin Trials; 2006 Jan; 1(1):15-34. PubMed ID: 18393777 [TBL] [Abstract][Full Text] [Related]
2. Older and new formulations of cladribine. Pharmacology and clinical efficacy in hematological malignancies. Robak T; Korycka A; Robak E Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):23-38. PubMed ID: 18221024 [TBL] [Abstract][Full Text] [Related]
3. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Robak T; Lech-Maranda E; Korycka A; Robak E Curr Med Chem; 2006; 13(26):3165-89. PubMed ID: 17168705 [TBL] [Abstract][Full Text] [Related]
4. Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Sigal DS; Miller HJ; Schram ED; Saven A Blood; 2010 Oct; 116(16):2884-96. PubMed ID: 20634380 [TBL] [Abstract][Full Text] [Related]
5. 2-Chlorodeoxyadenosine: a potent antimetabolite with major activity in the treatment of indolent lymphoproliferative disorders. Saven A; Piro LD Hematol Cell Ther; 1996 Dec; 38 Suppl 2():S93-101. PubMed ID: 9137962 [TBL] [Abstract][Full Text] [Related]
6. Clinical and toxicological aspects of the antineoplastic drug cladribine: a review. Guchelaar HJ; Richel DJ; Schaafsma MR Ann Hematol; 1994 Nov; 69(5):223-30. PubMed ID: 7948311 [TBL] [Abstract][Full Text] [Related]
7. 2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy: results of a multicentric experience. International Society for Chemo-Immunotherapy. Brugiatelli M; Holowiecka B; Dmoszynska A; Krieger O; Planinc-Peraica A; Labar B; Callea V; Morabito F; Jaksic B; Holowiecki J; Lutz D Ann Hematol; 1996 Aug; 73(2):79-84. PubMed ID: 8774616 [TBL] [Abstract][Full Text] [Related]
8. High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias. Betticher DC; Fey MF; von Rohr A; Tobler A; Jenzer H; Gratwohl A; Lohri A; Pugin P; Hess U; Pagani O Ann Oncol; 1994 Jan; 5(1):57-64. PubMed ID: 7909685 [TBL] [Abstract][Full Text] [Related]
9. Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Cladribine Study Group. Tobinai K; Ogura M; Hotta T; Kobayashi Y; Narabayashi M; Suzuki R; Kinoshita T; Kozuru M; Uike N; Ohashi Y Jpn J Clin Oncol; 1997 Jun; 27(3):146-53. PubMed ID: 9255268 [TBL] [Abstract][Full Text] [Related]
10. Cladribine in the treatment of chronic lymphocytic leukemia. Robak T Leuk Lymphoma; 2001 Feb; 40(5-6):551-64. PubMed ID: 11426528 [TBL] [Abstract][Full Text] [Related]
11. Older and new purine nucleoside analogs for patients with acute leukemias. Robak P; Robak T Cancer Treat Rev; 2013 Dec; 39(8):851-61. PubMed ID: 23566572 [TBL] [Abstract][Full Text] [Related]
12. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Robak T; Błasińska-Morawiec M; Błoński J; Hellmann A; Hałaburda K; Konopka L; Kotlarek-Haus S; Potoczek S; Hansz J; Dmoszyńska A; Urasiński I; Zdziarska B; Dwilewicz-Trojaczek J; Hołowiecki J; Skotnicki AB Eur J Haematol; 1999 Jan; 62(1):49-56. PubMed ID: 9918312 [TBL] [Abstract][Full Text] [Related]
13. Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma. Betticher DC; von Rohr A; Ratschiller D; Schmitz SF; Egger T; Sonderegger T; Herrmann R; Kroner T; Zulian GB; Cavalli F; Fey MF; Cerny T J Clin Oncol; 1998 Mar; 16(3):850-8. PubMed ID: 9508165 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma. Tobinai K; Uike N; Saburi Y; Chou T; Etoh T; Masuda M; Kawano F; Matsuoka M; Taguchi H; Makino T; Asano Y; Tamura K; Ohashi Y; Int J Hematol; 2003 Jun; 77(5):512-7. PubMed ID: 12841391 [TBL] [Abstract][Full Text] [Related]
15. Cladribine for multiple sclerosis: review and current status. Sipe JC Expert Rev Neurother; 2005 Nov; 5(6):721-7. PubMed ID: 16274330 [TBL] [Abstract][Full Text] [Related]
16. Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment. Robak T; Boński JZ; Kasznicki M; Góra-Tybor J; Hellmann A; Konopka L; Dmoszyńska A; Dwilewicz-Trojaczek J; Wołowiec D; Eur J Haematol; 2002 Jul; 69(1):27-36. PubMed ID: 12270059 [TBL] [Abstract][Full Text] [Related]
17. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. Kay AC; Saven A; Carrera CJ; Carson DA; Thurston D; Beutler E; Piro LD J Clin Oncol; 1992 Mar; 10(3):371-7. PubMed ID: 1346801 [TBL] [Abstract][Full Text] [Related]
18. Purine nucleoside analogues in the treatment of myleoid leukemias. Robak T Leuk Lymphoma; 2003 Mar; 44(3):391-409. PubMed ID: 12688309 [TBL] [Abstract][Full Text] [Related]
19. Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications. Robak T; Korycka A; Kasznicki M; Wrzesien-Kus A; Smolewski P Curr Cancer Drug Targets; 2005 Sep; 5(6):421-44. PubMed ID: 16178817 [TBL] [Abstract][Full Text] [Related]
20. Cladribine for the treatment of hematologic malignancies. Baltz JK; Montello MJ Clin Pharm; 1993 Nov; 12(11):805-13; quiz 860-2. PubMed ID: 7903917 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]